{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:46:25Z","timestamp":1773675985333,"version":"3.50.1"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T00:00:00Z","timestamp":1455235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0149007","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T18:53:19Z","timestamp":1455303199000},"page":"e0149007","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment"],"prefix":"10.1371","volume":"11","author":[{"given":"Bj\u00f6rn","family":"Vandewalle","sequence":"first","affiliation":[]},{"given":"Josep M.","family":"Llibre","sequence":"additional","affiliation":[]},{"given":"Jean-Jacques","family":"Parienti","sequence":"additional","affiliation":[]},{"given":"Andrew","family":"Ustianowski","sequence":"additional","affiliation":[]},{"given":"Ricardo","family":"Camacho","sequence":"additional","affiliation":[]},{"given":"Colette","family":"Smith","sequence":"additional","affiliation":[]},{"given":"Alec","family":"Miners","sequence":"additional","affiliation":[]},{"given":"Diana","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"F\u00e9lix","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2016,2,12]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.300.1.51","article-title":"Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population","volume":"300","author":"K Bhaskaran","year":"2008","journal-title":"JAMA"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/ije\/dyr164","article-title":"All-cause mortality in treated HIV-infected adults with CD4 >\/ = 500\/mm3 compared with the general population: evidence from a large European observational cohort collaboration","volume":"41","author":"C Lewden","year":"2012","journal-title":"International journal of epidemiology"},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/QAD.0b013e32835cae9c","article-title":"Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population","volume":"27","author":"AJ Rodger","year":"2013","journal-title":"Aids"},{"issue":"9787","key":"ref4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial","volume":"378","author":"CJ Cohen","year":"2011","journal-title":"The Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/QAD.0000000000000169","article-title":"Week 48 results from a randomized clinical trial of rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate vs. efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults","volume":"28","author":"CJ Cohen","year":"2014","journal-title":"Aids"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-154-7-201104050-00316","article-title":"Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1","volume":"154","author":"ES Daar","year":"2011","journal-title":"Annals of Internal Medicine"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"379","author":"E DeJesus","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1473-3099(11)70290-0","article-title":"Once daily dolutegravir (S\/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial","volume":"12","author":"J van Lunzen","year":"2011","journal-title":"The Lancet Infectious Diseases"},{"key":"ref9","unstructured":"Society EAC. Guidelines version 7.1. 2014."},{"key":"ref10","unstructured":"Young B, Debes R, Buchacz K, Scott M, Palella F, Brooks J, editors. HIV viral load monitoring frequency and risk of treatment failure among immunologically stable HIV-infected patients prescribed ART. 20th International AIDS Conference; 2014 July 20\u201325, 2014; Melbourne, Australia."},{"key":"ref11","unstructured":"Programs DoHaS. HIV Care and Treatment Service Utilization: 2012 Year End Report. 2014 April 2014. Report No."},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00126334-200310010-00009","article-title":"Impact of a Patient Education Program on Adherence to HIV Medication: A Randomized Clinical Trial","volume":"34","author":"C Goujard","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0277-9536(01)00167-8","article-title":"Increasing drug users\u2019 adherence to HIV treatment:results of a peer-driven intervention feasibility study","volume":"55","author":"RS Broadheada","year":"2002","journal-title":"Social Science & Medicine"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0738-3991(02)00127-1","article-title":"A medication self-management program to improve adherence to HIV therapy regimens","volume":"50","author":"SR Smith","year":"2003","journal-title":"Patient Education and Counseling"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1310\/BRBV-3941-H1PP-NDRY","article-title":"Efficacy of an Educational and Counseling Intervention on Adherence to Highly Active Antiretroviral Therapy: French Prospective Controlled Study","volume":"4","author":"C Pradier","year":"2003","journal-title":"HIV Clin Trials"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00126334-200310010-00007","article-title":"Impact of an educational program on efficacy and adherence with a twice-daily lamivudine\/zidovudine\/abacavir regimen in underrepresented HIV-infected patients","volume":"34","author":"MK Rawlings","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00002030-200003100-00008","article-title":"Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population","volume":"14","author":"DR Bangsberg","year":"2000","journal-title":"Aids"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1086\/323201","article-title":"Antiretroviral Therapy Adherence and Viral Suppression in HIV-Infected Drug Users: Comparison of Self-Report and Electronic Monitoring","volume":"33","author":"JH Arnsten","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"968","DOI":"10.7326\/0003-4819-134-10-200105150-00011","article-title":"A comparison study of multiple measures of adherence to HIV protease inhibitors","volume":"134","author":"H Liu","year":"2001","journal-title":"Ann Intern Med"},{"key":"ref20","first-page":"1115","article-title":"The Consistency of Adherence to Antiretroviral Therapy Predicts Biologic Outcomes for Human Immunodeficiency Virus\u2013Infected Persons in Clinical Trials","volume":"34","author":"S Mannheimer","year":"2002","journal-title":"HIV\/AIDS"},{"issue":"16","key":"ref21","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1097\/00002030-200211080-00010","article-title":"A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women","volume":"16","author":"AA Howard","year":"2002","journal-title":"Aids"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"e31591","DOI":"10.1371\/journal.pone.0031591","article-title":"Adherence to antiretroviral treatment and correlation with risk of hospitalization among comercially insured HIV patients in the United States","volume":"7","author":"PE Sax","year":"2012","journal-title":"PloS one"},{"key":"ref23","article-title":"Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database","author":"F Raffi","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"ref24","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/QAD.0b013e32832ba8ec","article-title":"Antiretroviral medication adherence and the development of class-specific antiretroviral resistance","volume":"23","author":"EM Gardner","year":"2009","journal-title":"Aids"},{"issue":"Suppl 3","key":"ref25","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1086\/533415","article-title":"Preventing HIV antiretroviral resistance through better monitoring of treatment adherence","volume":"197","author":"DR Bangsberg","year":"2008","journal-title":"The Journal of infectious diseases"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"e94495","DOI":"10.1371\/journal.pone.0094495","article-title":"Patterns of transmitted HIV drug resistance in Europe vary by risk group","volume":"9","author":"D Frentz","year":"2014","journal-title":"PloS one"},{"issue":"18","key":"ref27","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJMsa1214720","article-title":"Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples","volume":"369","author":"RP Walensky","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1524-4733.2007.00170.x","article-title":"Estimating the Rate of Accumulating Drug Resistance Mutations in the HIV Genome","volume":"10","author":"RS Braithwaite","year":"2007","journal-title":"Value Health"},{"issue":"9","key":"ref29","doi-asserted-by":"crossref","first-page":"e73269","DOI":"10.1371\/journal.pone.0073269","article-title":"Averting HIV Infections in New York City: A Modeling Approach Estimating the Future Impact of Additional Behavioral and Biomedical HIV Prevention Strategies","volume":"8","author":"J Kessler","year":"2013","journal-title":"PloS one"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1468-1293.2007.00507.x","article-title":"HIV in the UK 1980\u20132006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy","volume":"8","author":"AN Phillips","year":"2007","journal-title":"HIV Med"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/QAD.0b013e328344037a","article-title":"Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings","volume":"25","author":"AN Phillips","year":"2011","journal-title":"Aids"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","first-page":"e1002470","DOI":"10.1371\/journal.pcbi.1002470","article-title":"Determinants of sexual network structure and their impact on cumulative network measures","volume":"8","author":"BV Schmid","year":"2012","journal-title":"PLoS computational biology"},{"key":"ref33","unstructured":"Cohen C, Wohl C, Cavassini C, Henry K, Bloch M, Towner W, et al., editors. STaR Study: Single-Tablet Regimen Rilpivirine\/Emtricitabine\/Tenofovir DF Is Non-Inferior Compared to Efavirenz\/Emtricitabine\/Tenofovir DF and Improves Patient Reported Outcomes through Week 96. ICAAC; 2014 September 5\u20139, 2014; Washingtion DC, USA."},{"issue":"9","key":"ref34","doi-asserted-by":"crossref","first-page":"e44774","DOI":"10.1371\/journal.pone.0044774","article-title":"Cost-Effectiveness of the Third-Agent Class in Treatment-Naive Human Immunodeficiency Virus-Infected Patients in Portugal","volume":"7","author":"F Arag\u00e3o","year":"2012","journal-title":"PloS one"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jtbi.2009.06.011","article-title":"Modeling HIV persistence, the latent reservoir, and viral blips","volume":"260","author":"L Rong","year":"2009","journal-title":"J Theor Biol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1126\/science.8493571","article-title":"How Does HIV Cause AIDS?","volume":"260","author":"RA Weiss","year":"1993","journal-title":"Science"},{"issue":"4","key":"ref37","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1128\/JVI.67.4.1772-1777.1993","article-title":"Increased Viral Burden and Cytopathicity Correlate Temporally with CD4+ T-Lymphocyte Decline and Clinical Progression in Human Immunodeficiency Virus Type 1-Infected Individuals","volume":"67","author":"RI Connor","year":"1993","journal-title":"Journal of Virology"},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"a007096","DOI":"10.1101\/cshperspect.a007096","article-title":"HIV Latency","volume":"1","author":"RF Siliciano","year":"2011","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"11","key":"ref39","doi-asserted-by":"crossref","first-page":"e49492","DOI":"10.1371\/journal.pone.0049492","article-title":"Modelling HIV and MTB Co-Infection Including Combined Treatment Strategies","volume":"7","author":"S Ramkissoon","year":"2012","journal-title":"PloS one"},{"issue":"10","key":"ref40","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1128\/JCM.41.10.4531-4536.2003","article-title":"New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma","volume":"41","author":"S Palmer","year":"2003","journal-title":"J Clin Microbiol"},{"issue":"4","key":"ref41","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1371\/journal.ppat.0030046","article-title":"ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia","volume":"3","author":"F Maldarelli","year":"2007","journal-title":"PLoS pathogens"},{"issue":"3","key":"ref42","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/jmv.21405","article-title":"Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation","volume":"81","author":"S Bonora","year":"2009","journal-title":"J Med Virol"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/bulm.2001.0266","article-title":"HIV-1 Infection and Low Steady State Viral Loads","volume":"64","author":"D Callaway","year":"2002","journal-title":"Bull Math Biol"},{"key":"ref44","article-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection","year":"2013"},{"issue":"8","key":"ref45","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1086\/651419","article-title":"Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication","volume":"50","author":"JJ Parienti","year":"2010","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"3","key":"ref46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/QAI.0b013e31826cc592","article-title":"Patterns of adherence to raltegravir-based regimens and the risk of virological failure among HIV-infected patients: the RALTECAPS cohort study","volume":"61","author":"G Gras","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"ref47","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jtbi.2006.12.038","article-title":"Optimal drug treatment regimens for HIV depend on adherence","volume":"246","author":"O Krakovska","year":"2007","journal-title":"J Theor Biol"},{"issue":"7","key":"ref48","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs","volume":"14","author":"L Shen","year":"2008","journal-title":"Nature medicine"},{"issue":"3","key":"ref49","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.2649","article-title":"A quantitative basis for antiretroviral therapy for HIV-1 infection","volume":"18","author":"BL Jilek","year":"2012","journal-title":"Nat Med"},{"issue":"4","key":"ref50","doi-asserted-by":"crossref","first-page":"e61436","DOI":"10.1371\/journal.pone.0061436","article-title":"Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response","volume":"8","author":"J Vercauteren","year":"2013","journal-title":"PloS one"},{"issue":"1","key":"ref51","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/QAI.0b013e318134257a","article-title":"HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells\/mm3 on Long-Term Combination Antiretroviral Therapy Reach Same Mortality Rates as the General Population","volume":"46","author":"C Lewden","year":"2007","journal-title":"Acquir Immune Defic Syndr"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"654","DOI":"10.7326\/0003-4819-124-7-199604010-00006","article-title":"Immunopathogenic Mechanisms of HIV Infection","volume":"124","author":"A Fauci","year":"1996","journal-title":"Ann Intern Med"},{"key":"ref53","unstructured":"Administration DoHaA-TG. Australian Public Assessment Report for Rilpivirine. Australian Government, 2012 March 2012. Report No."},{"issue":"7","key":"ref54","doi-asserted-by":"crossref","first-page":"e2783","DOI":"10.1371\/journal.pone.0002783","article-title":"Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels","volume":"3","author":"JJ Parienti","year":"2008","journal-title":"PloS one"},{"issue":"5","key":"ref55","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/09540120701203337","article-title":"Modeling HIV transmission risk among Mozambicans prior to their initiating highly active antiretroviral therapy","volume":"19","author":"CR Pearson","year":"2007","journal-title":"AIDS Care"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0149007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T01:47:05Z","timestamp":1654307225000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0149007"}},"subtitle":[],"editor":[{"given":"Dimitrios","family":"Paraskevis","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2016,2,12]]},"references-count":55,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0149007","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,12]]}}}